MedTrace Logo

The Zeaxanthin and Visual Function Study

NCT00564902 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-03-29

Study results available
· View outcomes & findings →

Summary

To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.

Conditions

  • Age Related Macular Degeneration
  • Cognition Disorders

Interventions

DRUG

3R 3'R Zeaxanthin

8 mg per day during 12 months

DIETARY_SUPPLEMENT

Lutein

9 mg of Lutein during 12 months

DIETARY_SUPPLEMENT

Lutein and Zeaxanthin

8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months

Sponsors & Collaborators

  • Kowa Company, Ltd.

    collaborator INDUSTRY

  • IMAGE TECHNOLOGIES INC.

    collaborator INDUSTRY

  • Chrysantis, Inc.

    lead INDUSTRY

Principal Investigators

  • Stuart Richer, Ph. D. · North Chicago VA Medical Center

  • William Stiles, M.D. · North Chicago VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-05-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00564902 on ClinicalTrials.gov